Global Information
회사소개 | 문의 | 비교리스트

중국의 인플리시맙(Infliximab) 시장(2022-2031년)

Investigation Report on China´s Infliximab Market 2022-2031

리서치사 China Research and Intelligence
발행일 2022년 07월 상품코드 1105811
페이지 정보 영문 40 Pages 배송안내 1-2일 (영업일 기준)
가격
US $ 3,200 ₩ 4,193,000 Unprintable PDF (Single User License)
US $ 4,800 ₩ 6,290,000 Printable & Editable PDF (Enterprisewide License)


중국의 인플리시맙(Infliximab) 시장(2022-2031년) Investigation Report on China´s Infliximab Market 2022-2031
발행일 : 2022년 07월 페이지 정보 : 영문 40 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

중국이 인플리시맙 판매량은 2017-2021년간 약 19.0%로 성장하여, 2021년에는 3억 3,589만 위안에 이르렀습니다.

중국 정부의 엄격한 '제로 코로나' 정책 시행에 의해 중국의 인플리시맙 판매량과 매출은 2022년에 감소할 것으로 예측됩니다. 그러나, 2023년 초반 이후에는 COVID-19 관리 정책을 완화할 것으로 예상되기 때문에 2023-2026년간 회복 성장을 보일 전망입니다.

중국의 인플리시맙(Infliximab) 시장에 대해 조사분석했으며, COVID-19의 영향, 시장 규모, 제조업체 분석, 시장 전망 등의 정보를 제공합니다.

제1장 인플리시맙 관련 개념

  • 인플리시맙의 적응증
  • 중국의 인플리시맙 개발
  • 중국 정부의 인플리시맙 승인
  • 중국의 인플리시맙 판매에 대한 COVID-19의 영향

제2장 중국에서의 인플리시맙 판매(2017-2021년)

  • 인플리시맙 매출
    • 전체 매출
    • 지역별 매출
  • 인플리시맙 판매량
    • 전체 판매량
    • 지역별 판매량
  • 중국 인플리시맙 판매 : 투여 방법별(2017-2021년)
    • 주사
    • 기타 투여 방법 분석

제3장 중국의 주요 인플리시맙 제조업체 분석(2017-2021년)

  • 주요 인플리시맙 제조업체의 시장 점유율 분석
    • 시장 점유율 조사 : 판매량별
    • 시장 점유율 조사 : 판매량별
  • Janssen Biologics BV
    • 기업 개요
    • 중국에서의 REMICADE(Janssen의 인플리시맙) 판매

제4장 중국 다양한 제조업체의 인플리시맙 가격(2021-2022년)

  • Janssen Biologics BV(REMICADE)

제5장 중국의 인플리시맙 시장 전망(2022-2031년)

  • 중국의 인플리시맙 시장 개발 영향요인
    • 중국 인플리시맙 시장에 대한 COVID-19의 영향
    • 시장 성장 촉진요인과 기회
    • 시장 위협과 과제
  • 시장 규모 예측
  • 시장 동향 예측
LSH 22.08.04

List of Charts

  • Chart Infliximab Drugs Approved by Chinese Government, by 2022
  • Chart Sales Value of Infliximab in China, 2017-2021
  • Chart Sales Value of Infliximab in Regions of China, 2017-2021
  • Chart Sales Volume of Infliximab in China, 2017-2021
  • Chart Sales Volume of Infliximab in Regions of China,2017-2021
  • Chart Sales value and volume of infliximab injection in China 2017-2021
  • Chart Market Share of TOP3 Infliximab Manufacturers by Sales Value in China, 2017-2021
  • Chart Market Share of TOP3 Infliximab Manufacturers by Sales Volume in China, 2017-2021
  • Chart Profile of Janssen Biologics BV
  • Chart Sales Value of Janssen Biologics BV 's Infliximab in China, 2017-2021
  • Chart Sales Volume of Janssen Biologics BV 's Infliximab in China, 2017-2021
  • Chart Profile of Taizhou Mabtech Pharmaceutical Co., Ltd.
  • Chart Sales Value of Taizhou Mabtech Pharmaceutical Co., Ltd.'s Infliximab in China, 2017-2021
  • Chart Sales Volume of Taizhou Mabtech Pharmaceutical Co., Ltd. 's Infliximab in China, 2017-2021
  • Chart Hisun Biopharmaceutical Co., Ltd.
  • Chart Sales Value of Xi'an Hanfeng Pharmaceutical Co., Ltd.'s Infliximab in China, 2017-2021
  • Chart Sales Volume of Xi'an Hanfeng Pharmaceutical Co., Ltd.'s Infliximab in China, 2017-2021
  • Chart Prices of Janssen Biologics BV's Infliximab (Remicade ®) in Parts of China, 2021-2022
  • Chart Prices of Taizhou Mabtech Pharmaceutical Co., Ltd.'s Infliximab (Leiting®) in Parts of China, 2021-2022
  • Chart Prices of Hisun Biopharmaceutical Co., Ltd.'s infliximab(Anbaite®) in Parts of China, 2021-2022
  • Chart Forecast on sales of infliximab in China 2022-2031

Infliximab is a human-mouse chimeric IgG1 monoclonal antibody targeting tumor necrosis factor (TNF-α) (composed of human IgG1 constant region and mouse variable region). It is used to treat a variety of autoimmune diseases, including Crohn's disease, ulcerative colitis, rheumatoid arthritis, and ankylosing spondylitis. Infliximab was developed by Johnson & Johnson. In 2007, Infliximab entered the Chinese market. The Chinese infliximab market is completely dominated by Janssen, a Johnson & Johnson company, until 2021. Two local Chinese companies, Taizhou Mabtech Pharmaceutical Co., Ltd. and Hisun Biopharmaceutical Co., Ltd. are launching infliximab in 2021, making Janssen's infliximab a challenge in the Chinese market.

According to CRI's market research, since Infliximab entered the Chinese market in 2007, its sales have had an increasing trend. However, the sales in China are suboptimal compared to global sales. The main reason is that most patients in China cannot afford the expensive price. After Infliximab was included in the national medical insurance in 2019, the sales increased about 18.9% in 2020 and reached CNY335.89 million in 2021. The CAGR of infliximab's sales value in China is approximately 19.0% from 2017 to 2021.

According to CRI's market research and expert interviews, CRI sees different trends in 2022 and from 2023 to 2026 in China's infliximab market.

Sales volume and value of infliximab in China are expected to decline in 2022 as the Chinese government implements a strict "COVID-19 dynamic zeroing" policy that will prevent many healthcare facilities in China from operating normally. It is expected that the Chinese government will relax the COVID-19 control policy from early 2023 onwards, and thus the sales volume and sales value of infliximab in China will show a recovery growth from 2023-2026.

Topics covered:

  • The impact of COVID-19 on China's Infliximab market
  • Sales value of China's Infliximab 2017-2021
  • Competitive landscape of China's Infliximab market
  • Prices of Infliximab in China
  • Prices of Infliximab in China by regions and manufacturers
  • Analysis on factors affecting the development of China's Infliximab market
  • Prospect of China's Infliximab market from 2022 to 2026

Table of Contents

1 Relevant Concepts of Infliximab

  • 1.1 Indications for Infliximab
  • 1.2 Development of Infliximab in China
  • 1.3 Governmental Approval of Infliximab in China
  • 1.4 The Impact of COVID-19 on Infliximab sales in China

2 Sales of Infliximab in China, 2017-2021

  • 2.1 Sales Value of Infliximab
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Infliximab
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Regions
  • 2.3 Sales of Infliximab by Dosage Form in China, 2017-2021
    • 2.3.1 Injection
    • 2.3.2 Analysis of Other Dosage Forms

3 Analysis of Major Infliximab Manufacturers in China, 2017-2021

  • 3.1 Analysis of Market Share of Major Infliximab Manufacturers
    • 3.1.1 Investigation on Market Share by Sales Value
    • 3.1.2 Investigation on Market Share by Sales volume
  • 3.2 Janssen Biologics BV
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of REMICADE (Janssen's Infliximab) in China

4 Prices of Infliximab for Different Manufacturers in China, 2021-2022

  • 4.1 Janssen Biologics BV (REMICADE)

5 Prospect of Chinese Infliximab drug Market, 2022-2031

  • 5.1 Influential Factors of Chinese Infliximab Market Development
    • 5.1.1 The Impact of COVID-19 on Chinese Infliximab Market
    • 5.1.2 Market Drivers and Opportunities
    • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend
Back to Top
전화 문의
F A Q